Fen Ben and Cancer

Fenbendazole and cancer

https://karger.com/cro/article-pdf/18/1/856/4381509/000546362.pdf

Fenbendazole, inexpensive, widely accessible antiparasitic drug used in veterinary medicine

Patent expired in the early 1990s, making FBZ available as a generic drug

Case 1

An 83-year-old female

October 2021

Stage 4 breast cancer

Initially diagnosed in 2009

Treated 2009, bilateral mastectomy

Recurrence was diagnosed in 2021.

Liver biopsy, confirmed metastatic breast

Ascitic fluid confirmed metastatic breast carcinoma.

Magnetic resonance imaging of the spine, October 2021 metastatic breast cancer, T10, T12, L1, L2, L3, L4, L5, S1, S2, and the iliac bones.

A PET/CT scan on December 29, 2021, showed six hypermetabolic lung lesions

Largest was 2.8 × 1.5 cm

Hypermetabolic liver lesions, 2.9 × 1.7 cm

Hypermetabolic bone lesions, notably a 5.0 × 2.9 cm lytic lesion in L4, extending into the spinal canal, etc

The patient declined further conventional chemotherapy or radiation therapy and was placed under hospice care.

November 22, 2021

Self-administering FBZ daily at a dose of 222 mg.

In December 2021, she received fulvestrant injection, (an estrogen receptor blocker) intended to inhibit cancer growth

January 2022

Targeted radiation for two painful spinal metastases.

These tumors disappeared rapidly, relieving her pain within a few days.

Continued taking 222 mg/day of FBZ for 8 months.

During this time, her liver enzymes normalized

CA 27.29 tumor marker dropped from 316 (November 2021) to 36.6 (July 2022)

April 20, 2022,

PET scan confirmed the absence of any abnormal metabolic activity indicative of cancer.

June 2022

Patient was confirmed to have no evidence of active disease.

All treatments were discontinued, and she was considered to be in complete remission.

Follow-up monitoring was scheduled every 3–6 months.

Throughout her FBZ treatment, she continued her regular supplementation of vitamin D (5,000 IU) and a multivitamin.

Subsequent PET scans showed no abnormal metabolic activity.

The FBZ treatment period revealed no adverse effects at this dosage.

The patient remains recurrence-free and continues to take FBZ daily nearly 3 years after being declared to be in remission.

Joe Tipp’s Protocol

https://www.fenbendazole.org/fenbendazole-information/fenbendazole-dosage-guide/

Case 2, Prostate cancer, 75 year old man

Bone scans and CT scans, metastases in the spine, pelvic bones, and right humeral head

Conventional treatments

Complementary treatments

The use of FBZ coincided with continued regression of metastatic lesions and sustained undetectable PSA levels

After 26 months of sustained regression and no new progression, the patient remains in near-complete response and continues FBZ with conventional therapy

Case 3, 63-year-old man

Hip growth, melanoma.

PET-CT showed multiple hypermetabolic foci – peritoneal and retroperitoneal nodules, focal uptake in the stomach and small bowel, lesions in the right gluteus medius, quadratus femoris, and L5 vertebra.

Conventional and complementary treatments

The patient remains melanoma recurrence-free over 11 months after being declared to be in remission.

Case Presentations

All three patients, no reported adverse effects

Conclusion

FBZ demonstrates potential as a novel promising therapeutic option for repurposing in oncology.

Its ability to contribute to tumor regression and achieve disease remission warrants further clinical research to establish its efficacy and optimize its use.